Feature

Fed. Circ. Ruling Takes 'Blocking Patents' To New Places

Law360 (September 18, 2018, 7:07 PM EDT) -- The Federal Circuit's recent ruling invalidating patents on Acorda Therapeutics Inc.'s multiple sclerosis drug Ampyra could expand the impact of so-called blocking patents and may make it easier to show an invention is obvious, attorneys say.

The appeals court, in a 2-1 ruling last week, upheld a Delaware federal judge's ruling that four Acorda patents, which covered the administration of a medication to improve the walking of people with multiple sclerosis, would have been obvious at the time of the invention.

In reaching that conclusion, the court held that evidence of Ampyra's commercial success — the drug had $1.7 billion in...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!